Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Development of Immunocompetence01:22

Development of Immunocompetence

1.2K
The initiation of cell-mediated immunity can be observed as early as the third month of fetal growth, with active antibody-mediated immunity following approximately one month later.
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...
1.2K
Immunodeficiency Diseases01:25

Immunodeficiency Diseases

3.7K
Immunodeficiency disorders are conditions in which the immune system's ability to fight infectious disease and cancer is compromised or entirely absent. The immune system comprises a complex network of cells, tissues, and organs that work together to protect the body from potentially harmful invaders. When this system is deficient or not functioning properly, it leaves the body susceptible to infections, diseases, or other complications.
There are three main causes of immunodeficiency...
3.7K
Factors Affecting the Risk of Infection01:26

Factors Affecting the Risk of Infection

14.1K
The hosts' susceptibility to infection depends on several factors. The integrity of the skin and mucous membranes helps protect the body against microbial attacks. When the skin is altered, the chance of infection, limb loss, and even death increases.
The integrity and count of the white blood cells help the body resist pathogens and fight infection. When impaired, it reduces the body's resistance to pathogens. The acidic pH levels of the gastrointestinal, genitourinary tracts, and skin...
14.1K
Cell-mediated Immune Responses01:40

Cell-mediated Immune Responses

64.7K
Overview
64.7K
Active versus Passive Immunity01:31

Active versus Passive Immunity

8.6K
Immunity, along with the ability to limit pathogen growth to prevent significant body tissue damage, can be gained either by (1) actively developing an immune response within the individual after exposure to a pathogen or after getting vaccinated or (2) passively transferring immune components from an immune individual to one who is nonimmune. Both these forms of immunity can be found naturally and in medical practices.
Active Immunity
Active immunity refers to the resistance one develops...
8.6K
Special Features of Adaptive Immunity01:20

Special Features of Adaptive Immunity

3.7K
The adaptive immune system, a crucial component of the overall immune response, offers a highly specialized defense against pathogens. It involves specific cell types and features, enabling it to combat infections effectively and efficiently.
The primary cell types involved in adaptive immunity are T cells and B cells. Each type has a unique role in defending the body against pathogens. T cells are responsible for cell-mediated immunity. They identify and eliminate infected cells directly,...
3.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Clinical development of tacrolimus-resistant regulatory T cells to enable simultaneous immunosuppression and immune regulation.

Molecular therapy. Advances·2026
Same author

Lipid nanoparticle mRNA delivery preserves CAR T cell cytotoxicity and limits exhaustion compared to electroporation.

Molecular therapy. Nucleic acids·2026
Same author

The Impact of Evaluation Strategy on Sepsis Prediction Model Performance Metrics in Intensive Care Data: Retrospective Cohort Study.

Journal of medical Internet research·2026
Same author

Prediction and risk evaluation of delirium after surgery in older patients: development and internal validation of an algorithm from the prospective BioCog cohort study.

British journal of anaesthesia·2026
Same author

mRNA-based CAR T cell engineering: Unmodified mRNA enables high CAR expression without innate immune activation in T cells.

Molecular therapy. Nucleic acids·2026
Same author

HLA matching or CRISPR editing of HLA class I/II enables engraftment and effective function of allogeneic human regulatory T cell therapy in a humanized mouse transplantation model.

Nature communications·2025

Related Experiment Video

Updated: May 3, 2026

Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses
10:13

Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses

Published on: May 6, 2019

8.2K

To be, or not to be immunocompetent.

Hans-Dieter Volk, Petra Reinke

    Critical Care (London, England)
    |February 7, 2014
    PubMed
    Summary

    Targeting negative immune regulatory molecules can reverse sepsis-induced immunoparalysis. This approach improves survival in experimental sepsis, offering new strategies for patient recovery and overcoming immune suppression.

    Area of Science:

    • Immunology
    • Critical Care Medicine
    • Translational Research

    Background:

    • Severe sepsis impairs the inflammatory-immune response, impacting patient outcomes.
    • Immunosuppression in sepsis is characterized by enhanced expression of negative regulatory molecules.
    • Negative regulatory molecules are implicated in tumor immune evasion.

    Purpose of the Study:

    • To investigate the potential of targeting negative immune regulatory molecules to reverse sepsis-induced immunoparalysis.
    • To explore novel therapeutic strategies for improving sepsis recovery by modulating immune responses.

    Main Methods:

    • Review of recent studies on targeting negative regulatory molecules (e.g., CD25, CTLA-4, PD-1/PD-L) in cancer and sepsis models.
    • Analysis of the role of these molecules in sepsis-associated immune suppression.

    More Related Videos

    An Immunological Model for Heterotopic Heart and Cardiac Muscle Cell Transplantation in Rats
    09:25

    An Immunological Model for Heterotopic Heart and Cardiac Muscle Cell Transplantation in Rats

    Published on: May 8, 2020

    7.2K
    Author Spotlight: Advancing Immune Monitoring in Critical Care Patients Using Whole Blood Assays
    06:03

    Author Spotlight: Advancing Immune Monitoring in Critical Care Patients Using Whole Blood Assays

    Published on: September 20, 2024

    1.5K

    Related Experiment Videos

    Last Updated: May 3, 2026

    Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses
    10:13

    Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses

    Published on: May 6, 2019

    8.2K
    An Immunological Model for Heterotopic Heart and Cardiac Muscle Cell Transplantation in Rats
    09:25

    An Immunological Model for Heterotopic Heart and Cardiac Muscle Cell Transplantation in Rats

    Published on: May 8, 2020

    7.2K
    Author Spotlight: Advancing Immune Monitoring in Critical Care Patients Using Whole Blood Assays
    06:03

    Author Spotlight: Advancing Immune Monitoring in Critical Care Patients Using Whole Blood Assays

    Published on: September 20, 2024

    1.5K

    Main Results:

    • Targeting negative regulatory molecules can reverse immunoparalysis in experimental sepsis.
    • This strategy has shown promise in improving survival rates in preclinical sepsis models.
    • Similar approaches have successfully reversed tumor progression by enhancing anti-tumor immunity.

    Conclusions:

    • Targeting negative immune regulatory molecules represents a novel therapeutic avenue for sepsis.
    • Reversing sepsis-induced immunoparalysis can improve clinical outcomes and patient survival.
    • This approach offers new opportunities to overcome immune suppression in severe sepsis.